Oxford launches first human trial of a vaccine targeting Bundibugyo Ebola

Monday, July 13, 2026Science & ClimateWell-covered3 frames

How left and right are reading this

Both agree: An unapproved Ebola strain now has a first human trial, with stockpiled doses waiting on proof the vaccine is safe and can trigger immunity.
They split on: Whether the story is about building protection early for outbreak-hit communities, or about proving institutional readiness without relaxing the standards of evidence.

The University of Oxford has launched the first human Phase 1 clinical trial of a vaccine against Bundibugyo ebolavirus.
The trial is intended to support the response to an Ebola outbreak affecting the Democratic Republic of the Congo and Uganda.
The study, known as BD-Ebov, will evaluate the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged 18 to 55 in Oxford.
Recruitment for the trial has begun, and vaccinations are expected to start in the coming weeks pending regulatory approval.
The vaccine was developed by scientists at Oxford's Vaccine Group and Pandemic Sciences Institute using the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine.
The Serum Institute of India said it manufactured and stockpiled about 620,000 doses of the vaccine candidate and supplied 4,000 investigational doses for the Phase 1 study.
There is currently no approved vaccine for the Bundibugyo strain of Ebola, making the trial an early test of a candidate for a strain without an authorized shot.
What remains unresolved is whether the vaccine will prove safe and generate a useful immune response in people; the current trial is designed to answer those early questions before any later-stage testing.

Monday, July 13, 2026Science & ClimateWell-covered3 frames

How left and right are reading this

Both agree: An unapproved Ebola strain now has a first human trial, with stockpiled doses waiting on proof the vaccine is safe and can trigger immunity.
They split on: Whether the story is about building protection early for outbreak-hit communities, or about proving institutional readiness without relaxing the standards of evidence.

The University of Oxford has launched the first human Phase 1 clinical trial of a vaccine against Bundibugyo ebolavirus.
The trial is intended to support the response to an Ebola outbreak affecting the Democratic Republic of the Congo and Uganda.
The study, known as BD-Ebov, will evaluate the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged 18 to 55 in Oxford.
Recruitment for the trial has begun, and vaccinations are expected to start in the coming weeks pending regulatory approval.
The vaccine was developed by scientists at Oxford's Vaccine Group and Pandemic Sciences Institute using the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine.
The Serum Institute of India said it manufactured and stockpiled about 620,000 doses of the vaccine candidate and supplied 4,000 investigational doses for the Phase 1 study.
There is currently no approved vaccine for the Bundibugyo strain of Ebola, making the trial an early test of a candidate for a strain without an authorized shot.
What remains unresolved is whether the vaccine will prove safe and generate a useful immune response in people; the current trial is designed to answer those early questions before any later-stage testing.

Facts first. Then every angle.